Microsatellite alterations in african americans with head and neck cancer.
OBJECTIVE
To determine the genetic differences between African Americans (AA) and Non-African Americans (NAA) with head and neck squamous cell carcinoma (HNSCC).


METHODS
DNA was obtained from tumor tissues and peripheral blood from 18 AA and 19 NAA patients with HNSCC. Microsatellite analysis using a fluorescent technique was performed on chromosomal arms 1p, 3p, 4q, 9p, 13q, and 17p. Statistical analyses were performed on the molecular and clinical outcome data.


RESULTS
Based on the Surveillance, Epidemiologic, and End Result (SEER) data from southeast Michigan, the incidence rate of HNSCC in AA has been higher than for NAA, and the overall 5-year relative survival rate is lower for AA than NAA (36.2% vs. 47.6%). In this study, we found that the rate of loss of heterozygosity of chromosomal arms 1p, 3p, 4q, 9p, 13q, and 17p ranged from 68.8% to 83.3% for HNSCC in AA and from 66.7% to 90.0% in NAA. The difference in the rates of microsatellite alterations in chromosomal arms 3p, 4q, and 9p between AA and NAA were between 12.5% and 20% and were not statistically significant.


CONCLUSIONS
The incidence and clinical outcomes for AA with HNSCC are different from that of NAA in southeast Michigan. In our group of patients with HNSCC, differences in rates of microsatellite alterations and survival were found between AA and NAA; however, these differences were not statistically significant. We conclude that genetic difference, as determined by the rates of microsatellite alterations, is not predictive of outcome difference between AA and NAA HNSCC patients.
Department of Otolaryngology-Head and Neck Surgery, Wayne State University, Detroit, MI, USA. gyoo@med.wayne.edu
George H
GH
Yoo
Nghia X
NX
Nguyen
Wei
W
Du
Ann G
AG
Schwartz
Susan
S
Land
Ho-Sheng
HS
Lin
Danny
D
Kewson
Leslie L
LL
Murphy
Dave
D
Cilluffo
John F
JF
Ensley
Michael A
MA
Tainsky
D000328:Adult; D000368:Aged; D044383:Black People / Q000235:genetics* / Q000706:statistics & numerical data; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002869:Chromosome Aberrations; D002874:Chromosome Mapping; D003430:Cross-Sectional Studies; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D015994:Incidence; D019656:Loss of Heterozygosity; D008297:Male; D008824:Michigan; D018895:Microsatellite Repeats / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D010039:Otorhinolaryngologic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011446:Prospective Studies; D018426:SEER Program; D015996:Survival Rate; D044465:White People / Q000235:genetics / Q000706:statistics & numerical data; D001741:Black or African American
D004273:DNA, Neoplasm